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samples from asymptomatic subjects (34.3% [62/181] vs. 25.4%
[114/449]; p=0.03). Potential pathogens in symptomatic subjects
were more likely to be treated than were pathogens in asymp-
tomatic subjects (83.9% [52/62] vs. 26.3% [30/114]; p<0.0001).
Conclusions: The majority of surveillance BAL cultures were non-
diagnostic and the results rarely altered the management of
asymptomatic lung transplant recipients. Routine mycobacterial
culture and PCP staining were of particularly low yield.
32
Impact of Drug Interactions on Choice of Antifungal
Therapy in Treating IFI. A Case Report of Use of
Posaconazole to Treat Fusarium Soft Tissue Infection in a
Liver Transplant Patient on Sirolimus
Shariq Haider. McMaster University, Division of Infectious
Diseases, 3V42 1200 Main St West Hamilton Ontario Canada
Background: Fungal infections are the most common cause of cu-
taneous infections in solid organ transplant patients. We describe
a case of soft tissue infection of the toe caused by Fuasarium
chlamydosporum and Candida guilliermondii in a liver transplant
patient on sirolimus, and discuss the pharmacokinetic interactions
of sirolimus and the new triazoles and their impact on treatment
choices.
Case: A 57 year old male post liver transplant in 2005 for Budd
Chiari Syndrome on Sirolimus 2mg daily, cellcept 750mg po bid,
developed an invasive soft tissue infection of his 5th toe after
spending a few weeks at his cottage walking bare feet. He noted
marked swelling and purple discoloration of his 5th toe two weeks
after returning from his cottage in the summer of 2007 (Figure 1).
A biopsy of the toe was done and identified on culture Candida
guilliermondii and Fusarium chlamydosporum. Susceptibility test-
ing for both isolates was done (Table 1). Patient was treated with
posaconazole 400mg po bid for 6 months with complete resolu-
tion of infection. Sirolimus was dose adjusted to 1mg everyother
day due to significant incr. in AUC of Sirolimus through the CYP450
isoenzymes.
Figure 1
Table 1. Susceptibility profile
Candida guilliermondii
Fluconazole 2mg/L Susceptible
Itraconazole 0.25mg/L Susceptible
5-Flucytosine 0.03mg/L Susceptible
Amphotericin B 0.5 mg/L No interpretation
Voriconazole 0.12 mg/L
Caspofungin 0.25mg/L
Fusarium Chlamydosporum
Amphotericin B 0.5mg/L
Fluconazole 32 mg/L
Ketoconazole 1mg/L
Itraconazole 2mg/L
Voriconazole 0.5mg/L
Discussion: This case illustrates the benefits of new triazoles in
treating IFI, but highlights the drug interactions of the new tria-
zoles: voriconazole and posaconazole on treatment choices with a
review of the literature around these drug interactions.
33
Respiratory Viral Infections in Renal Transplant Recipients
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Paulo School of Medicine, São Paulo, Brazil; 2Nephrology,
Department of Internal Medicine, Santa Casa de São Paulo School
of Medicine, São Paulo, Brazil; 3Virology Laboratory, Institute of
Tropical Medicine, University of São Paulo (IMTSP-USP), São
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Background: Solid organ transplant (SOT) recipients are partic-
ularly susceptible to community-acquired respiratory viruses and
they also appear more likely to experience pulmonary and extra-
pulmonary complications. Atypical clinical presentation caused by
influenza virus A and B or other virus are increasingly recognized
as a cause of morbidity including recipients rejection and chronic
allograft dysfunction.
Objectives: To determine the frequency and clinical aspects in-
cluding allograft complications of influenza A and B infection and
influenza-like illness caused by respiratory syncytial virus (RSV),
adenovirus, parainfluenza virus 1, 2 and 3 in renal transplant re-
cipients.
Methods: 434 nose-and-throat washes specimens were prospec-
tively collected from each patient every three weeks (5.78 samples
per patient) as well as clinical signs and symptoms of respiratory vi-
ral infections on 75 renal transplanted patients during six months.
Direct immunofluorescence (DIF) was the virological method used
for detecting respiratory virus.
Results: Influenza and flu-like symptoms were observed in 23.5%
of the subjects, including fever (temperature higher than 37.8°C),
nasal congestion, sore throat, cough, sneezing, headache, myal-
gia, weakness, fatigue and loss of appetite. Diagnosis of symp-
tomatic and asymptomatic patients with virus isolation collected
from nose-and-throat washes was able to detect only six episodes
of virus infection: 2 RSV, 2 parainfluenza, 1 influenza A and 1 in-
fluenza B. No significant difference was observed when serum cre-
atinine at six month was compared with baseline serum creatinine
(1.74±0.65, 1.84±0.55, p=0.312) and there were no serious com-
plications after virus infections during the six months period of
follow up.
Conclusion: Respiratory virus infections were not associated with
significant morbidity in renal transplant recipients.
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Characteristics of Transplant Recipients who Developed
Influenza in 2007-08 Despite Influenza Vaccination
Sherif Mossad. Department of Infectious Diseases, Cleveland
Clinic, Ohio, Cleveland, USA
Background: Influenza vaccination is less immunogenic in trans-
plant recipients than healthy people. Influenza A (H1N1) and B
circulating viruses during the 2007-2008 epidemic were different
from those contained in this season' s vaccine.
Objective: To describe clinical and immunological characteristics
of 15 transplant recipients who developed influenza despite in-
fluenza vaccination (group A), and compare them to 6 transplant
recipients who developed influenza in the absence of influenza
vaccination (group B), 13 transplant recipients who did not develop
